All News

ViewPoints: Signs of promise for Merck KGaA and GSK's 'Keytruda killer'?

Ref: ViewPoints Desk

Tags: ViewPoints Merck KGaA Merck & Co. GSK BMS Roche AstraZeneca Lung Cancer Clinical Research (R&D)bintrafusp alfa Keytruda

Biogen cuts annual guidance as Tecfidera generics hit Q3 results

Ref: Biogen, This is Money, NASDAQ, MarketWatch

Tags: Top Story Biogen Corporate Affairs Tecfidera

Priority Review Granted to Ascentage Pharma's New Drug Application for Olverembatinib (HQP1351), the First Third-Generation BCR-ABL Inhibitor in China

Ref: PR Newswire

Tags: Press Release Ascentage Pharma Leukaemias NMPA Regulatory Affairs olverembatinib

Nomination committee in Oncopeptides established

Ref: PR Newswire

Tags: People News Oncopeptides Corporate Affairs

Lilly hires external advisor in wake of FDA issues at manufacturing site

Ref: Bloomberg, Fidelity, Eli Lilly

Tags: Top Story Lilly COVID-19 FDA Regulatory Affairs bamlanivimab

CureLab Oncology Establishes Operations in the Gulf Region

Ref: PR Newswire

Tags: Press Release CureLab Oncology Corporate Affairs

TLC Appoints Thomas H. Bliss as Chief Business Officer

Ref: GlobeNewswire

Tags: People News Amgen AstraZeneca Baxter J&J Takeda TLC Corporate Affairs

Pharming receives Orphan Drug Designation from the European Commission for leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS)

Ref: Pharming

Tags: Press Release Pharming European Commission Regulatory Affairs leniolisib

PCI Biotech: Preclinical research collaboration with big pharma ended

Ref: GlobeNewswire

Tags: Press Release AstraZeneca PCI Biotech Corporate Affairs Licensing

Novartis receives US Food and Drug Administration (FDA) Orphan Drug Designation for branaplam (LMI070) in Huntington’s disease (HD)

Ref: Novartis

Tags: Press Release Novartis FDA Regulatory Affairs branaplam